title: A new bis-indole, KARs, induces selective M arrest with specific spindle aberration in neuroblastoma cell line SH-SY5Y.
abstract: KARs, new semisynthetic antitumor bis-indole derivatives, were found to be inhibitors of tubulin polymerization with lower toxicity than vinblastine or vincristine, used in chemotherapy. Here, we compare the effect of KARs with those of vinblastine and vincristine on cell viability, cell proliferation, and cell cycle in neuroblastoma cell line (SH-SY5Y). At concentrations of the different compounds equivalent in causing 50% of inhibition of cell growth, KARs induced a complete arrest in the G2/M phase, whereas vinblastine and vincristine induced a partial arrest in both G0/G1 and G2/M. Moreover, a combination of KAR-2 and W13 (an anticalmodulin drug) qualitatively caused a similar arrest in both G0/G1 and G2/M than vinblastine. Levels of cyclin A and B1 were higher in KARs-treated cells than in vinblastine- or vincristine-treated cells. Cdc2 activity was much higher in KAR-2 than in vinblastine-treated cells, indicating a stronger mitotic arrest. The effect of KAR2 and vinblastine on microtubules network was analyzed by immunostaining with anti-tubulin antibody. Results indicated that KAR-2-induces the formation of aberrant mitotic spindles, with not apparent effect on interphase microtubules, whereas vinblastine partially destroyed interphase microtubules coexisting with normal and aberrant mitotic spindles.
authors.affiliation: Department of Biochemistry and Molecular Biology, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Faculty of Chemistry, University of Barcelona, Barcelona, Spain.
authors.forename: B
authors.initials: B
authors.lastname: Comín-Anduix
authors.forename: N
authors.initials: N
authors.lastname: Agell
authors.forename: O
authors.initials: O
authors.lastname: Bachs
authors.forename: J
authors.initials: J
authors.lastname: Ovádi
authors.forename: M
authors.initials: M
authors.lastname: Cascante
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D017209:Apoptosis; D016203:CDC2 Protein Kinase / Q000187:drug effects / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects; D002875:Chromosomes / Q000187:drug effects; D019925:Cyclin A / Q000187:drug effects / Q000378:metabolism; D019926:Cyclin B / Q000187:drug effects / Q000378:metabolism; D056744:Cyclin B1; D016195:G2 Phase / Q000187:drug effects*; D006801:Humans; D007399:Interphase / Q000187:drug effects; D008870:Microtubules / Q000187:drug effects; D008938:Mitosis / Q000187:drug effects*; D009447:Neuroblastoma / Q000473:pathology*; D008941:Spindle Apparatus / Q000187:drug effects*; D014407:Tumor Cells, Cultured; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D000972:Antineoplastic Agents, Phytogenic; C534699:CCNB1 protein, human; D019925:Cyclin A; D019926:Cyclin B; D056744:Cyclin B1; C118249:KAR 3; C118250:KAR 4; D014747:Vinblastine; C107832:deacetoxyvinzolidine; D016203:CDC2 Protein Kinase